CD30-positive cutaneous T-cell lymphoma and response to Brentuximab Vedotin: 2 illustrative cases

Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):319-23. doi: 10.1016/j.clml.2012.12.008. Epub 2013 Jan 10.

Authors

Kabir Mody¹, Jill S Wallace, Diane M Stearns, George Bowers, Shannon R Lacy, Norman B Levy, Kathryn A Zug, Frederick Lansigan

Affiliation

¹ Hematology and Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA. frederick.lansigan@hitchcock.org

PMID: 23313068
DOI: 10.1016/j.clml.2012.12.008

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Aged, 80 and over
Brentuximab Vedotin
Humans
Immunoconjugates / adverse effects
Immunoconjugates / therapeutic use*
Ki-1 Antigen / immunology*
Lymphoma, T-Cell, Cutaneous / drug therapy*
Lymphoma, T-Cell, Cutaneous / immunology*
Male

Substances

Immunoconjugates
Ki-1 Antigen
Brentuximab Vedotin